Guanhao Biotech (300238) 2025 Annual Report Brief Analysis: Revenue Increase without Profit Growth, Company Accounts Receivable Are Relatively Large

According to publicly available data compiled by Securities Star, Guanhao Biotech (300238) recently released its 2025 annual report. As of the end of this reporting period, the company’s total operating revenue was 388 million yuan, up 2.72% year-over-year, while net profit attributable to shareholders was 24.346 million yuan, down 11.2%. On a quarterly basis, the fourth quarter’s total revenue was 94.269 million yuan, a decrease of 5.11% year-over-year, and net profit attributable to shareholders was -2.3725 million yuan, a decline of 465.64%. During this period, Guanhao Biotech’s accounts receivable were relatively large, with receivables accounting for 215.45% of the latest annual net profit attributable to shareholders.

This figure is below most analysts’ expectations, as they previously forecasted a net profit of approximately 38.52 million yuan for 2025.

The financial data released in this report shows average performance. The gross profit margin was 77.13%, a decrease of 2.93 percentage points year-over-year; net profit margin was 3.81%, down 13.32 percentage points. Total selling, administrative, and financial expenses amounted to 222 million yuan, accounting for 57.13% of revenue, a slight decrease of 0.15%. Net asset value per share was 2.15 yuan, an increase of 5.11% year-over-year; operating cash flow per share was 0.27 yuan, up 44.23%; earnings per share were 0.09 yuan, down 10.0%.

The explanations for significant changes in financial items in the financial statements are as follows:

1. Financial expenses changed by 148.0%, due to an increase in special loans for the Tianhao Zhongshan Pharmaceutical Technology Project.
2. Net cash flow from operating activities changed by 44.23%, due to increased sales collections during this period.
3. Net cash flow from investing activities changed by 57.4%, due to payments for the Tianhao Zhongshan Pharmaceutical Technology Project in the same period last year.
4. Net cash flow from financing activities changed by -51.79%, due to a decrease in project loans for the Tianhao Zhongshan Pharmaceutical Technology Project.
5. Changes in cash and cash equivalents amounted to 50.41%, driven by increased sales collections.
6. Long-term equity investments decreased by 95.73%, due to the purchase of equity in joint ventures.
7. Construction in progress increased by 609.01%, due to investments in the Tianhao Zhongshan Pharmaceutical Technology Project—cream technology upgrade.
8. Right-of-use assets decreased by 55.27%, due to depreciation of right-of-use assets.
9. Short-term borrowings decreased by 25.05%, due to repayment of bank loans.
10. Long-term borrowings increased by 36.7%, due to additional special loans for the Tianhao Zhongshan Pharmaceutical Technology Project.
11. Lease liabilities decreased by 71.99%, due to lease payments.

According to Securities Star’s valuation analysis tools:

• Business Evaluation: The company’s ROIC last year was 3.05%, indicating weak capital returns. The net profit margin was 3.81%, suggesting that after accounting for all costs, the company’s products or services have low added value. Historically, over the past 10 years, the median ROIC was 3.4%, with relatively weak investment returns. The worst year was 2022, with an ROIC of -46.22%, indicating extremely poor returns. The company’s financial performance has been generally average, with 14 annual reports since listing, including two years of losses, reflecting a fragile business model.

• Business Model: The company’s performance mainly relies on R&D and marketing efforts. A detailed analysis of these drivers is necessary.

• Business Breakdown: Over the past three years (2023/2024/2025), the net return on operating assets was 5.8%, 3.8%, and 3.4%, respectively. Net operating profits were 21.0725 million, 16.6078 million, and 14.7873 million yuan, with net operating assets of 365 million, 440 million, and 431 million yuan.

  Over the same period, the company’s working capital to revenue ratio was 0.22, 0.20, and 0.21, with working capital (funds invested by the company in operations) at 88.664 million, 74.946 million, and 83.32 million yuan, and revenue at 404 million, 377 million, and 388 million yuan.

The financial health assessment tools suggest:

1. Pay attention to the company’s cash flow status (cash and cash equivalents to current liabilities are only 95.36%).
2. Monitor accounts receivable status (accounts receivable to profit ratio has reached 215.45%).

This content is compiled by Securities Star based on publicly available information, generated by AI algorithms (Network Credit Record 310104345710301240019), and does not constitute investment advice.